cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLC10.15829/1728-8800-2011-3-76-82cardiovascular-1837Research ArticleМНЕНИЕ ПО ПРОБЛЕМЕOPINION ON A PROBLEMФармакокинетика и фармакодинамика β-адреноблокатора бисопролола. От механизма действия к клиническим особенностямPharmacokinetics and pharmacodynamics of a β-adrenoblocker bisoprolol: from mechanisms of action to clinical featuresОстроумоваО. Д.OstroumovaO. D.

профессор кафедры клинической фармакологии и пропедевтики внутренних болезней

Москва, Тел.: (495) 303-02-54, 303-9307

Ostroumova.olga@mail.ruСмолярчукЕ. А.SmolyarchukE. A.

профессор кафедры клинической фармакологии и пропедевтики внутренних болезней

Москва

Первый Московский государственный медицинский университет им. И.М.СеченоваI.M. Sechenov First Moscow State Medical University2011200620111037682Copyright © Остроумова О.Д., Смолярчук Е.А., 20112011Остроумова О.Д., Смолярчук Е.А.Ostroumova O.D., Smolyarchuk E.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/1837

Представлены механизмы действия β-адреноблокаторов (β-АБ). Обсуждены особенности фармакокинетики, фармакодинамики, лекарственного взаимодействия высокоселективного β-АБ бисопролола. Приведены данные об эффективности и безопасности его применения при артериальной гипертонии, ишемической болезни сердца, хронической сердечной недостаточности, в т.ч. при наличии сопутствующих заболеваний.

The authors discuss the action mechanisms of β-adrenoblockers (β-AB), as well as pharmacokinetics, pharmacodynamics, and drug interaction of a highly selective β-AB bisoprolol. The paper presents the data on bisoprolol effectiveness and safety in arterial hypertension, coronary heart disease, chronic heart failure, and their combination with other diseases.

β-адреноблокаторбисопрололартериальная гипертонияишемическая болезнь сердцахроническая сердечная недостаточностьβ-adrenoblockerbisoprololarterial hypertensioncoronary heart diseasechronic heart failureReferencesКлиническая фармакология. Под ред. В.Г.Кукеса, издание 4. Москва, “ГЭОТАР-Медиа” 2008; 392-5.Клиническая фармакология. Под ред. В.Г.Кукеса, издание 4. Москва, “ГЭОТАР-Медиа” 2008; 392-5.Smith C, Teitler M. Beta-blocker selectivity at cloned human beta1 and beta2 — adrenergic receptors. Cardiovasc Drugs Ther 1999; 13: 123.Smith C, Teitler M. Beta-blocker selectivity at cloned human beta1 and beta2 — adrenergic receptors. Cardiovasc Drugs Ther 1999; 13: 123.Диагностика и лечение артериальной гипертензии. Ж Систем гиперт 2010; 3: 5-26.Диагностика и лечение артериальной гипертензии. Ж Систем гиперт 2010; 3: 5-26.Keim HJ. Behandlung der leichten bis mittelschweren essentiellen Hypertonie mit Bisoprolol. Therapiewoche 1988; 38: 3507.Keim HJ. Behandlung der leichten bis mittelschweren essentiellen Hypertonie mit Bisoprolol. Therapiewoche 1988; 38: 3507.Nakanishi T. Effect of bisoprolol hemifumarate on the diurnal variation of blood pressure in patients with essential hypertension. Current Ther Res 1992; 5: 779.Nakanishi T. Effect of bisoprolol hemifumarate on the diurnal variation of blood pressure in patients with essential hypertension. Current Ther Res 1992; 5: 779.Haasis R, Bethge H. Exercise blood pressure and heart rate reduction 24 and 3 hours after drug intake in hypertensive patients following 4 weeks of treatment with bisoprolol and metoprolol: a randomized multicentre double-blind study (BISOMET). Eur Heart J 1987; 8: 103-13.Haasis R, Bethge H. Exercise blood pressure and heart rate reduction 24 and 3 hours after drug intake in hypertensive patients following 4 weeks of treatment with bisoprolol and metoprolol: a randomized multicentre double-blind study (BISOMET). Eur Heart J 1987; 8: 103-13.Giesecke HG. Three years experience with bisoprolol in the treatment of mild to moderate hypertension. J Cardiovasc Pharmacol 1990; 16 (Suppl 5): S175.Giesecke HG. Three years experience with bisoprolol in the treatment of mild to moderate hypertension. J Cardiovasc Pharmacol 1990; 16 (Suppl 5): S175.Hoffler D, Morgenstern HO. Age dependence of therapy result and risk in the treatment of arterial hypertension? J Cardiovas Pharmacol 1990;16 (Suppl.5): 184-8.Hoffler D, Morgenstern HO. Age dependence of therapy result and risk in the treatment of arterial hypertension? J Cardiovas Pharmacol 1990;16 (Suppl.5): 184-8.Prager G. Langzeitbehandlung der essentiellen Hypertonie mit Bisoprolol: Eine multizentrische Monotherapiestudie unter Berucksichtigung des Belastungshochdrucks. Merck KGaA, Darmstadt, 1985.Prager G. Langzeitbehandlung der essentiellen Hypertonie mit Bisoprolol: Eine multizentrische Monotherapiestudie unter Berucksichtigung des Belastungshochdrucks. Merck KGaA, Darmstadt, 1985.Amabile G, Serradimigni A. Comparison of bisoprolol with nifedipine for treatment of essential hypertension in the elderly: comparative double-blind trial. Eur Heart J 1987; 8 (Suppl.M): 65-9.Amabile G, Serradimigni A. Comparison of bisoprolol with nifedipine for treatment of essential hypertension in the elderly: comparative double-blind trial. Eur Heart J 1987; 8 (Suppl.M): 65-9.Buhler FR, Berglund G, Anderson OK, et al. Double-blind of the cardioselective b-blockers bisoprolol and atenolol in hypertension: the Bisoprolol International Multicenter Study (BIMS). J Cardiovas Pharmacol 1986; 8 (Suppl.11):122.Buhler FR, Berglund G, Anderson OK, et al. Double-blind of the cardioselective b-blockers bisoprolol and atenolol in hypertension: the Bisoprolol International Multicenter Study (BIMS). J Cardiovas Pharmacol 1986; 8 (Suppl.11):122.CIBIS Investigators and Committees: A randomized trial of betablockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994; 90: 1765-73.CIBIS Investigators and Committees: A randomized trial of betablockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994; 90: 1765-73.CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353: 9-13.CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353: 9-13.Thomas von Arnim for the TIBBS Investigators. Prognostic significance of transient Ischimic episodes; response to treatment shows improved prognosis. Results of the Total Ischemic Burden Bisoprolol Study (TIBBS) Follow-up. JACC 1996; 28(1): 20-4.Thomas von Arnim for the TIBBS Investigators. Prognostic significance of transient Ischimic episodes; response to treatment shows improved prognosis. Results of the Total Ischemic Burden Bisoprolol Study (TIBBS) Follow-up. JACC 1996; 28(1): 20-4.Gosse P, Roudaut R, Herrero G, Dallocchio M. b-blockers vs angiotensin-converting enzyme inhibitors in hypertension: effects on left ventricular hypertrophy. J Cardiovasc Pharmacol 1990; 16(Suppl 5): 145-50.Gosse P, Roudaut R, Herrero G, Dallocchio M. b-blockers vs angiotensin-converting enzyme inhibitors in hypertension: effects on left ventricular hypertrophy. J Cardiovasc Pharmacol 1990; 16(Suppl 5): 145-50.Hoeffler D. Zur monotherapie der hypertonie mit einem lang wirksamen betablocker, Therapiewoche 1988; 38: 391.Hoeffler D. Zur monotherapie der hypertonie mit einem lang wirksamen betablocker, Therapiewoche 1988; 38: 391.Frithz G, Weiner L. Effects of bisoprolol on blood pressure, serum lipids and HDL-cholesterol in essential hypertension. Eur J Clinical Pharmacol 1987; 32: 77-80.Frithz G, Weiner L. Effects of bisoprolol on blood pressure, serum lipids and HDL-cholesterol in essential hypertension. Eur J Clinical Pharmacol 1987; 32: 77-80.Lichtman JH, Krumholz HM, Yun Wang. Risk and Predictors of Stroke After Myocardial Infarction Among the Elderly: Results From the Cooperative Cardiovascular Project. Circulation 2002; 3: 1082-7.Lichtman JH, Krumholz HM, Yun Wang. Risk and Predictors of Stroke After Myocardial Infarction Among the Elderly: Results From the Cooperative Cardiovascular Project. Circulation 2002; 3: 1082-7.Janka HU. Influence of bisoprolol on blood glucose, glucosuria, and haemoglobin A1 in noninsulin-dependent diabetics. J Cardiovasc Pharmacol 1986; 8 Suppl 11: S96-9.Janka HU. Influence of bisoprolol on blood glucose, glucosuria, and haemoglobin A1 in noninsulin-dependent diabetics. J Cardiovasc Pharmacol 1986; 8 Suppl 11: S96-9.Chatterjee SS. The cardioselective and hypotensive effects of bisoprolol in hypertensive asthmatics. Cardiovasc Pharmacol 1986; 8: Suppl 11: 74-7.Chatterjee SS. The cardioselective and hypotensive effects of bisoprolol in hypertensive asthmatics. Cardiovasc Pharmacol 1986; 8: Suppl 11: 74-7.Broekmann CPM. Bisoprolol and hypertension: effects on sexual functioning in men. J Sex Marital ther 1992; 4: 325.Broekmann CPM. Bisoprolol and hypertension: effects on sexual functioning in men. J Sex Marital ther 1992; 4: 325.Van de Ven LLM, Van Leeuwen JTM, Smit AJ. The influence of chronic treatment with betablockade and angiotensin converting enzyme inhibition on the peripheral blood flow in hypertensive patients with and without concomitant intermittent claudication. A comparative cross-over trial. VASA 1994; 23: 357-62.Van de Ven LLM, Van Leeuwen JTM, Smit AJ. The influence of chronic treatment with betablockade and angiotensin converting enzyme inhibition on the peripheral blood flow in hypertensive patients with and without concomitant intermittent claudication. A comparative cross-over trial. VASA 1994; 23: 357-62.

The authors declare that there are no conflicts of interest present.